OBJECTIVE： To systematically evaluate therapeutic efficacy and safety of different dosage regimens of apremilast in the treatment of psoriatic arthritis， and to investigate the optimal dosage regimens （dose， frequency of dosing， treatment course）. METHODS： Retrieved from Wanfang database， VIP， CJFD， CBM， PubMed， Embase， Ebsco and Cochrane library， “www.clinictrials.gov”， randomized controlled trial （RCTs） about therapeutic efficacy [the proportion of patients with ACR scoring criteria improvement degree≥20％ （ACR20 response rate）； HAQ-DI score] and safety [the incidence of adverse drug event] of different regimens of apremilast （trial group） versus placebo （control group） in treatment of psoriatic arthritis were collected from database establishment to March 27， 2018. After quality evaluation and data extraction for clinical studies meeting inclusion criteria， Meta-analysis was performed by using RevMan 5.3 statistical software. RESULTS： Totally 6 studies were included， involving 2 443 patients. The results of Meta- analysis showed that for daily dose， there was no statistical significance in ACR20 response rate or HAQ-DI score among patients with daily dose of 40， 60 mg whether treatment course was 16 weeks or 24 weeks （all P＞0.05）. The incidence of diarrhea [OR＝0.69， 95％CI（0.50，0.95）， P＝0.02]， headache [OR＝0.65， 95％CI（0.44，0.95）， P＝0.03] and nausea in patients with daily dose 40 mg were significantly lower than patients with daily dose 60 mg. For dosing frequency， there was no statistical significance in ACR20 response rate， HAQ-DI score or the incidence of ADR among patients receiving same daily dose （40 mg） once a day or twice a day. For treatment course， when the daily dose was 40 mg， there was no statistical significance in ACR20 response rate and HAQ-DI score between 16 weeks and 24 weeks （all P＞0.05）. When the daily dose was 60 mg， ACR20 response rate of patients receiving 16 weeks of treatment was significantly higher than that of patients receiving 24 weeks of treatment [OR＝1.35， 95％ CI（1.08，1.71）， P＝0.01]； there was no statistical significance in HAQ-DI score （P＝0.78）. Sensitivity analysis showed that after excluding the studies with great heterogeneity， when treatment course was 16 weeks， the response rate of ACR20 in patients receiving daily dose of 40 mg was significantly lower than those receiving daily dose of 60 mg [OR＝0.71， 95％CI（0.55，0.92）， P＝0.02]. There was no significant change from the original results. CONCLUSIONS： For apremilast in the treatment of psoriatic arthritis， therapeutic efficacy of patients receiving daily dose of 60 mg was better than those of patients receiving daily dose of 40 mg； as the extension of medication time， the advantage gradually weakened. 16 weeks of treatment course may be enough. Prolonged medication duration did not significantly increase therapeutic efficacy. For specific dosage regimens， individual differences， compliance and financial burden should be taken into account. The above results need to be verified by more high-quality clinical studies.